上市前藥物和醫(yī)療器械安全性信息主要來(lái)自臨床試驗(yàn)，而觀察受試者對(duì)試驗(yàn)藥物和器械反應(yīng)的是研究者，因此，研究者的不良事件報(bào)告至關(guān)重要。為幫助研究者確認(rèn)臨床研究期間非預(yù)期的安全性信息并遵守安全性報(bào)告要求，美國(guó)食品藥品管理局（FDA）于2021年9月發(fā)布了“研究者職責(zé)-研究性藥物和器械的安全性報(bào)告”指導(dǎo)原則（草案），詳細(xì)說(shuō)明了對(duì)研究者在IND和IDE研究中向申請(qǐng)人和倫理委員會(huì)報(bào)告的要求。我國(guó)目前還沒(méi)有類似的指導(dǎo)原則，詳細(xì)介紹FDA的該指導(dǎo)原則，以期對(duì)我國(guó)新藥和新醫(yī)療器械研究者在臨床研究期間識(shí)別非預(yù)期的安全信息并按要求及時(shí)報(bào)告有幫助并對(duì)該方面的監(jiān)管有所啟示。

The safety information of drugs and medical devices prior to marketing mainly comes from clinical trials, and it is the investigators who observe the subjects' responses to the investigational drugs and devices. Therefore, adverse event reports from investigators are critically important. To help investigators identify unanticipated safety information during clinical investigation and comply with safety reporting requirements, FDA issued the Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices Guidance for Industry (Draft) in September 2021.The requirements for investigators to report to the sponsors and instituttional review boards in IND and IDE studies are described in detail. At present, there is no similar guidance in China. The guidance of FDA is introduced in detail, which is expected to be helpful for Chinese investigators of new drugs and new medical devices to identify unanticipated safety information during clinical research and report it in time as required, and also to enlighten China's supervision in this regard.

R951